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Lotion is a useful vehicle for active ingredients used to treat skin disease because it can be applied to
the scalp, can cover large areas of skin, and it is easy to spread due to low viscosity. An emulsion lotion
(EL) containing 2-methacryloyloxyethyl phosphorylcholine n-butyl methacrylate copolymer (PMB) as
an emulsiﬁer that provides controlled-release was developed. Diphenhydramine (DPH) was used as a
model drug. Formulation with 5% DPH, 5% soybean oil, and 4% PMB in water was emulsiﬁed using a
high-pressure homogenizer. Polysorbate 80 (TO) was used instead of PMB for comparison. They were
applied in vitro to Yucatan micropig intact or stripped skin at a practical dose (2 mL/cm2). For stripped
skin, penetration of DPH from 4% PMB EL was slower than that from 1% TO EL; results for intact skin
were similar. The same phenomenon was observed with application to rabbit skin in vivo. When 4%
PMB EL dried on the skin, it made a thin ﬁlm matrix incorporating the oil phase, which controlled the
release of DPH. The release rate could be controlled by the ratio of oil phase to PMB. The EL with PMB
shows promise as a vehicle for long-acting treatment of skin diseases.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Skin is an attractive site for systemic drug delivery, and many
new vehicles have been developed that promote good skin per-
meation [1]. In addition, topical delivery of drugs for skin diseases
is effective with few systemic side effects. The choice of vehicle is
made based on the type of skin condition. Ointments, creams, and
lotions are common dosage forms. Lotion is especially convenient
for use on the scalp (or other site with hair) or to cover large areas
because it has low viscosity and is easy to spread. However, lotion
does possess some disadvantages: drugs with low water solubility
require solubilizing agents and procedures; the formulation of
lotion is affected by the vaporization of some ingredients after
application to skin that leaves drug and additives on the skin
surface, which can cause irritation; and the amount of drug per
unit area is relatively small and the duration of effectiveness is
short when applied on damaged skin because lotion does not
provide controlled release as an ointment does [10]. Thus, a new
vehicle consisting of an oil-in-water (o/w) emulsion lotion (EL),ll rights reserved.
: þ81 42 723 3585.which can accommodate poorly water-soluble drugs in the oil
phase and provides controlled release, was developed.
Polymers are often employed to control drug release, with
carboxyvinyl polymer and hydroxypropylmethyl cellulose com-
monly used for this purpose. However, these polymers do not
have solubilizing or emulsifying properties. Therefore, a polymer
is needed with solubilizing or emulsifying properties that can
provide controlled release. The PMB, 2-methacryloyloxyethyl
phosphorylcholine (MPC) n-butyl methacrylate (BMA) copolymer,
possesses both hydrophilic and hydrophobic characteristics. The
MPC also has excellent biocompatibility [12] and is used for
contact lens [3]. Since the MPC unit is extremely hydrophilic, the
copolymer with the MPC unit can be dissolved in water. Some
drugs can be solubilized by PMB [4,8,5]. The PMB also is used in
cosmetics to moisturize skin [6]. Since the molecular weight of
PMB is as high as 600,000, it may remain on the skin surface and
so is likely to be safer than conventional surfactant which some-
times irritates skin. We previously reported that skin penetration
of 2-ethylhexyl methoxycinnnamate, which is a UV absorber, was
inhibited when PMB was used as an emulsiﬁer [2]. Thus, PMB
was tested as an emulsiﬁer for the EL that provides sustained
drug release. Diphenhydramine (DPH), which is a widely used
antihistamine for allergy relief, is a liquid insoluble in water, and
capable of rapidly penetrating skin [9], was used as the model
A. Ishikawa et al. / Results in Pharma Sciences 2 (2012) 16–22 17drug in this study. EL containing DPH and PMB was prepared, and
penetration of DPH into skin was determined through in vitro and
in vivo experiments. In addition, the mechanism of sustained
release of DPH from EL was studied.2. Materials and methods
2.1. Materials
DPH (JP grade) was obtained from Nippon Bulk Yakuhin (Osaka).
PMB (Lipidure-PMBs; MPC: BMA¼8:2) was supplied by NOF Co.,
Ltd (Tokyo) as a 5% solution. Polyoxyethylene (20) sorbitan mono-
oleate (TO) was a gift from Nikko Chemicals Co., Ltd (Tokyo).
Soybean oil (SO, reagent grade) was purchased from Wako Pure
Chemical Industries (Osaka). Other reagents were of analytical
grade.
2.2. Preparation of lotion
DPH itself or DPH mixed with SO was used as oil phase, and a
PMB solution of the appropriate concentration was added to the
oil phase. Pre-emulsiﬁcation was performed using a mixer (Quick
Homomixer LR-1 Mizuho, Osaka) at 3000 rpm for 2 min. The
mixture was then introduced into a high-pressure homogenizer
(Microﬂuidizers, Mizuho) and passed through 10 times at a
pressure of 10,000 psi. The standard formulation consisted of 5%
DPH, 5% SO, 4% PMB, and water (PMB4% EL). For preparation of
PMB8% EL, a commercial PMB solution was lyophilized and the
PMB powder was dissolved in water at an appropriate concentra-
tion. TO was used as emulsiﬁer instead of PMB for comparison.
An EL consisting of 10% DPH, 10% SO, and 2% TO was prepared
using the procedure described above, followed by mixing at the
same volume of 8% PMB solution (TO1%þPMB4% EL). The stan-
dard formulation prepared pre-emulsiﬁcation was used as com-
parison (PMB4%-pre EL).
The mean diameter of droplets in the prepared EL was measured
by dynamic light scattering (DLS, ELS-800, Otsuka Electric, Osaka)
at a dilution of 200. The mean diameter was calculated using
cumulant method. Each sample was measured doublicated and at
least 3 samples were used.
Particle shape was observed with transmission electron micro-
scopy (TEM) (JEM1200EX, Jeol, Tokyo) at 80 kV with negative
staining by phosphotungstic acid. It was done in Hanaichi Ultra-
Structure Research Institute (Okazaki, Japan).
2.3. In vitro skin permeation study
The skin permeation study was performed under two condi-
tions, inﬁnite dose conditions (inﬁnite dose) and the practical
small amount application recommended in OECD guideline 428
(practical dose).
Yucatan micropig (YMP) skin sets frozen at 80 1C were
purchased from Charles River Japan, Inc. (Kanagawa, Japan). Skin
was thawed at 20–25 1C for approximately 30 min, followed by
removal of the adhering fat layer using scissors and a grater, and
cut into appropriate sizes (intact skin). YMP intact skin has the
stratum corneum (SC) consists of about 20-layer, a part of SC was
removed from intact skin with adhesive tape (Scotchs313, 3 M,
Tokyo) 15 times (stripped skin) to make a model of damaged skin.
Skin penetration was measured in a modiﬁed Franz diffusion cell
apparatus [effective area, 1.1 cm2; receptor, 16 mL isotonic phos-
phate buffered solution (pH 7.1) maintained at 37 1C mixed with a
star-head magnet at 600 rpm].
For the inﬁnite dose condition, skin was mounted directly on
the cell, a 2.0-mL aliquot of EL was poured into the donor phase,and the donor phase was occluded. At predetermined times,
200-mL aliquots were withdrawn from the receptor compartment.
The same volume of fresh solution was added to the receptor
compartment after withdrawal to maintain constant volume. At
27 h after application, skin was removed from the cell, washed
with puriﬁed water, gently dried, and used for further testing.
For the practical dose, EL was spread on the skin at 2 mL/cm2,
and the skin was mounted on the cell. The donor phase was not
occluded. At 4, 14, and 24 h after application, 200-mL aliquots
were withdrawn from the receptor compartment and skin was
removed from the cell and used for further tests without washing
to determine the mass balance of DPH.
After the skin permeation study, skin was stripped 10 times
(intact skin) or 5 times (stripped skin) with adhesive tape (Scotch
CC1820-Bx-J, 3 M) to determine the amount of DPH near the surface
of skin, followed by soaking in methanol. The skin was then
separated into the epidermis and dermis by the heat separation
method [7]. Methanol was added to each part, and the epidermis
and dermis were homogenized and centrifuged at 3000 rpm for
5 min, and the supernatant ﬁltered with a membrane ﬁlter (0.45 mm
for epidermis and 0.20 mm for dermis). The DPH concentration in
the solutions obtained was determined using HPLC.
2.4. In vivo skin permeation study
Rabbits (Japanese white, males, body weight ca. 3 kg) were
used for the in vivo skin permeation study. The hair of the back
was removed using an electric hair clipper followed by depilatory
cream the day before application. The EL was spread at 2 mL/cm2.
After 4-h application, SC was stripped 5 times with adhesive tape,
followed by sacriﬁce of the rabbit and isolation of the skin. The
skin was separated into the epidermis and dermis using the heat
separation method. The remaining process followed was the same
as that of the in vitro study. This study was approved by the Ethics
Committee of Showa Pharmaceutical University.
2.5. In vitro release test
Two types of release tests were arranged for the inﬁnite and
practical dose. For the inﬁnite dose study, DPH release was
determined by dialysis using a cellulose dialysis tube and JP XV
dissolution test apparatus (Toyama Sangyo, Osaka). One mL of EL
and 10 mL of water were placed in a rotation basket covered with
a dialysis membrane ﬁlter (#36, Wako Pure Chemical). The
release test was done at a rotation speed of 100 rpm, dissolution
medium of 900 mL at pH 7 phosphate buffer solution. At pre-
determined time intervals, 5 mL of medium were removed and
fresh medium was added. DPH concentration was determined by
absorbance at 218 nm.
For the practical dose, release from dried EL was determined
using a glass plate and oil clear paper. The EL was applied to the
glass plate at 20 mL/10 cm2 followed by drying placed in room at
25 1C for 2 h. A piece of oil clear paper (Gatsby, Mandom, Osaka) was
placed on the glass plate for adsorbed oil. The amount of oil released
at 0 h was calculated from the weight difference of the paper before
and after oil absorption. Then, the glass plate was placed upside
down on the oil clear paper for 1 or 2 h, and the test paper was
changed. Amounts of DPH released at 0, 1, 2, and 4 h after drying
were determined. DPH absorbed to the paper was extracted with
methanol and absorbed amount was determined using HPLC.
2.6. Analytical method
DPH concentrations were determined by an HPLC instru-
ment (Shimadzu, Kyoto) equipped with a spectrophotometric
detector (SPD-6A). The DPH were eluted from the column
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ambient temperature with a mobile phase of 0.1% phosphoric acid
solution-methanol (55:45), at ﬂow rate of 1 mL/min. DPH was
detected at 230 nm. The retention time of DPH was about 9 min
and no interference peak of skin component was observed.
2.7. Statistical analysis
The amount of DPH on or permeated into the skin was
determined for at least 3 experiments and the data subjected to
analysis of variance (ANOVA) followed by Dunnett’s test using TO1%
EL as a control. A value of Po0.05 was considered signiﬁcant.3. Results and discussion
3.1. Characterization of emulsions
Various formulations of ELs were prepared and oil droplet size in
ELs determined by DLS is shown in Table 1. When only DPH wasFig. 1. TEM photograph of PMB 4% EL with negative staining by phosphotungstic
acid. Bar in the photograph shows 100 nm.
Table 2
Skin permeation parameters after application of 2 mL/cm2 of various formulations to i
Flux (mg/cm2/h) Lag time (h) SC (mg/cm2)
TO1%EL 17.873.3 5.472.1 31.075.9
PMB1%EL 16.875.5 6.474.1 29.4710.8
PMB4%EL 16.571.8 7.571.1 13.57 4.3a
All formulations contain 5% DPH and 5% SO.
Each value represents the mean7S.D. of three experiments.
a Signiﬁcantly different (po0.05) from TO1%.
Table 1
Oil droplet size in emulsions as measured by DLS.
Formulation (%) Droplet size (nm)
DPH SO Emulsiﬁer 1 Day 1 Month
PMB4% without SO 5 0 4 14737381 C
PMB1% EL 5 5 1 18378 191713
PMB4% EL 5 5 4 250729 25479
TO1% EL 5 5 1 124731 119714
C; Creaming was observed.used as the oil phase, oil droplet size was greater than 500 nm one
day after preparation, and creaming occurred within a month, even
if the PMB concentration was 4% and the Microﬂuidizer was used.
Thus, SO (a lipophilic oil) was added to the oil phase. The DPH was
mixed with SO (oil phase) then the PMB solution (water phase) was
added. Pre-emulsiﬁed EL was not stable and phase separation
occurred. A stable emulsion was obtained using the Microﬂuidizer.
The size of oil droplet measured by DLS was ca. 200 nm for PMB ELs.
PMB is a polymer, there was a possibility that PMB trap oil in its
polymer chain and so called emulsion was not formed. Thus, TEM
images of PMB4% EL was observed (Fig. 1). The image shows
relatively uniform spheres, which size were slightly smaller than
those obtained by DLS measurement (100–200 nm). It indicates that
PMB is not a so called ‘‘surfactant,’’ a stable EL was obtained with a
high shear rate emulsifying.
The EL using the nonionic surfactant TO also was prepared as a
control, which was stable when prepared by the same method as
PMB ELs, and the droplet sizes were smaller than those of PMB ELs.
3.2. Skin permeation in vitro
3.2.1. Inﬁnite dose
The cumulative permeation of DPH from 2 mL TO1%, PMB1%,
and PMB4% ELs through YMP intact skin was determined. The
steady-state ﬂux and lag time, which were calculated from the
linear section of time-cumulative amount plots, and skin con-
centrations are shown in Table 2. No signiﬁcant difference in ﬂux
or lag time was found among the formulations. Amounts of DPH
in skin after application of PMB4% EL tended to be less than those
of other formulations, and concentration in SC was signiﬁcantly
lower than that of TO1% EL.
The amount of DPH in the EL was 100mg; the total amount of
DPH that penetrated and permeated the skin was ca. 1 mg for all
formulation. Thus, the amount of DPH was adequate and inﬁnite
conditions are maintained to 27 h after application. In contrast, the
partition coefﬁcient of DPH between SO and water (P) was high
(log P¼4.6), so that the amount of DPH in the water phase of the
donor EL was only about 50 mg. Thus, DPH in the oil phase should be
released into the water phase as the DPH in the water phase
decreases due to penetration of DPH into the skin. DPH release from
the oil phase appeared to be sustained for PMB4% EL. Release of DPH
was determined by dialysis. Release of DPH from PMB4% EL was 25%
at 1 h and 77% at 6 h, which was less than that from TO1% EL (71% at
1 h and 90% at 2 h). However, the ﬂux of DPH through skin is not as
great as release from the oil phase; thus, the difference in formulation
does not affect skin permeation.3.2.2. Practical dose
In practical use, the amount of emulsion applied onto the skin
is small. Thus, the water in the EL evaporates, which changes the
condition of the emulsion, disrupts its structure, can result in
inversion from o/w to w/o or make a thin ﬁlm consisting of non-
vaporized materials, drug, oil, or surfactant. When EL was appliedntact skin.




A. Ishikawa et al. / Results in Pharma Sciences 2 (2012) 16–22 19on intact skin and stripped skin, the amount of DPH in SC near the
surface, in the epidermis, in the dermis, and in the receptor phase
was determined at 4, 14, and 24 h after application.
Fig. 2 shows the distribution of DPH in the skin and receptor
phase. For intact skin (solid lines), the DPH in SC decreased with
time, but about one-half of the DPH applied remained near the
skin surface after 24 h application. The DPH levels in the epider-
mis and dermis were almost constant, ca. 10–20% of the dose
within 24 h. The DPH in the receptor phase increased with time,
but less than 20% of the applied DPH permeated within 24 h.
Some points were signiﬁcantly different for formulations (in SC
and dermis at 4 h after application of PMB4% EL and in the
receptor phase at 24 h after application), but formulation had
little effect on the skin distribution of DPH. This suggests that the
rate-limiting step of DPH skin permeation is related to the skin
barrier, not the formulation of the EL.
For stripped skin (dashed lines), DPH in SC decreased imme-
diately, with only 20% remaining at 4 h after application and
almost none at 14 h. The DPH in the epidermis reached a peak at
4 h and then decreased at 24 h. The amount of DPH in the dermisFig. 2. Skin distribution of DPH after application of 2 mL/cm2 EL to YMP skin in vitro. (a)
Solid line, intact skin; dashed line, stripped skin. n, TO1% EL; J, PMB1% EL; K, PMB
difference versus TO 1% EL applied the skin with the same condition.
Fig. 3. Skin distribution of DPH at 4 h after application of 2 mL/cm2 EL to rabbit skin in
mean7SD of three experiments. *Signiﬁcantly difference versus TO 1% EL.and receptor phase tended to be high after application of TO1%
and PMB1% ELs. In contrast, after application of PMB4% EL, the
DPH in the SC was signiﬁcantly greater, but in the dermis it was
signiﬁcantly less than after application of TO1% EL. In the
epidermis, no signiﬁcant difference among formulations was
found, although the DPH level tended to be low after application
of PMB4% EL.
The permeation of DPH through stripped skin was faster than
that through intact skin, because the thickness of SC, main barrier of
skin permeation was decreased. Ohtani et al. [10] reported that the
difference in skin permeation between intact and stripped skin was
greater for a lotion than for a cream or ointment. However, after
application of PMB4% EL to stripped skin, the distribution of DPH
was similar to that of intact skin, which suggests that the release of
DPH was controlled by the vehicle for PMB4% EL.
3.3. Skin permeation in vivo
An in vitro skin permeation study showed increased skin con-
centration of the drug due to lack of clearance by blood ﬂow [11].Stratum corneum near the surface of skin; (b) Epidermis; (c) Dermis; (d) Receptor
4% EL. Each point represents the mean7SD of three experiments. *Signiﬁcantly
vivo: (a) Stratum corneum; (b) Epidermis; (c) Dermis. Each point represents the
Fig. 5. Release proﬁles of DPH from various formulations. Twenty mL EL was
spread over 10 cm2 on the glass plate, followed by drying for 2 h, when the release
test was initiated: n, TO1% EL; J, PMB1% EL;K, PMB4% EL; m, TO1%þ PMB4% EL;
~, PMB4% -pre EL. Each point represents the mean of at least three experiments.
Fig. 6. Higuchi’s plots of DPH release from the EL using various concentrations of
PMB:J,1%;’, 2%; n, 3%;K, 4%;&, 8%, Each point represents the mean7SD of at
least three experiments.
A. Ishikawa et al. / Results in Pharma Sciences 2 (2012) 16–2220Thus, EL was applied to rabbit skin in vivo with practical dose. Fig. 3
shows the amount of DPH in skin per unit area at 4 h after
application of EL. Only 5% of the applied dose remained on or in
the skin after application of TO1% EL. Rabbit skin resistance is less
than that of human skin [13], DPH permeated the skin rapidly and
almost all of the DPH was cleared by the bloodstream. Amounts of
DPH in the SC, epidermis, and dermis after application of PMB4% EL
were signiﬁcantly greater than those after application of TO1% EL,
which suggests that DPH permeation was controlled by DPH release
from the vehicle when PMB4% EL was used.
3.4. Condition of EL after drying
Signiﬁcant differences among formulations were observed
after application of practical usage condition. Under practical
usage conditions, only nonvolatile ingredients remained on the
skin surface because of evaporation of water from the EL. Usually,
an o/w emulsion converts into a w/o emulsion during drying
because of water evaporation increasing the relative oil concen-
tration. Thus, the weight of oil absorbed onto the paper was
measured after drying EL on a glass plate (Fig. 4). An application
of 20 mL EL contained 1 mg of DPH, 1 mg of SO, and 0.2 or 0.8 mg
surfactant or polymer. For TO1% EL, the amount of oil absorbed
was high as 70%. For PMB1% EL, the amount of absorbed oil was
less than that of TO1% EL, and for PMB4% EL, only a very small
amount of nonvolatile ingredients was absorbed onto the paper.
These results indicate that PMB prevents absorption of the oil
phase onto the test paper.
Since PMB is a polymer, it has the ability to form ﬁlms that can
prevent oil absorption onto the paper. Thus, two types of emulsions
were prepared for comparison. One used TO as an emulsiﬁer, adding
PMB after preparation of the emulsion (TO1%þPMB4% EL). The
other was pre-emulsiﬁed PMB4% only, without using a high-
pressure emulsifying procedure with the Microﬂuidizer (PMB4%-
pre EL). For TO1%þPMB4% EL, the amount of absorbed oil was
similar to that of TO1% EL. Oil absorption was prevented for PMB4%-
pre EL even though the effect was low, which indicates emulsiﬁca-
tion with PMB is necessary to prevent oil absorption onto the paper.
A stable emulsion also is important. It appears as if PMB is adsorbed
on the surface of the oil phase, and this condition is maintained after
water evaporation.
3.5. Release of DPH
The features of dried PMB4% EL were different from those of
other ELs. DPH release proﬁles from dried emulsions were
compared (Fig. 5). The release of DPH after 2-h drying (time 0 hFig. 4. The amount of oil phase absorbed onto the paper after 2 h drying the ELs.
20 mL EL was spread over 10 cm2 on the glass plate. The column and bar show the
mean7SD of at least 3 experiments. *Signiﬁcantly difference versus TO 1% EL.in the graph) was high for TO1% EL (70%), TO1%þPMB4% EL (60%),
and PMB4%-pre EL (50%), and low for PMB4% EL (3%). These
percentages were similar to the amount of oil absorbed to the
paper, which indicates that DPH is released with SO.
The release proﬁles of DPH from PMB4% EL seem to obey
Higuchi’s equation (i.e., a linear plot is obtained from a plot of
released amount as a function of the square root of time). Fig. 6
shows the Higuchi plots of DPH release from ELs with various
concentrations of PMB. In all cases, the plots show good linearity.
For PMB1% EL, a burst of DPH release occurred at time 0. But when
the concentration of PMB was greater than 2%, only a small amount
of DPH was released at time 0. The slope of the approximation lines
decreased with increasing PMB concentration in the EL, therefore, it
was deﬁned as the apparent release rate (k). The concentrations of
SO and DPH varied from 1% to 15% and 3–8%, respectively. The
release proﬁles were a Higuchi type in all cases, and k increased
with increasing SO and DPH concentrations.
Table 3 summarizes the results of release tests. For experi-
ments involving a high oil phase (DPHþSO) to PMB ratio (45), a
burst was observed at time 0 h. The amount of DPH released (Q)
at time t could then be described as:
Q ¼ kOtþQ0 ð1Þ
where Q0 is released amount at time 0 h. Investigation of the
effect of formulation on k revealed that the ratio of the amount of
the oil phase (SOþDPH) at time 0 h (Moil) to the amount of PMB
Table 3
The amount of ingredients after drying and apparent release rate obtained from Higuchi’s plots.
Formulation (%) Applied amount (mg/cm2) Released amount




b k (mg/cm2/Oh) c R2 d
PMB SO DPH PMB SO DPH SOe DPHf PMB SO DPH
Standard 4 5 5 80 100 100 3 0.3 80 97 100 2.46 9.2 0.996
PMB
1% 1 5 5 20 100 100 54 29.0 20 75 71 7.28 35.3 0.999
2% 2 5 5 40 100 100 15 5.8 40 91 94 4.62 22.3 0.989
3% 3 5 5 60 100 100 5 2.3 60 97 98 3.25 14.8 0.984
8% 8 5 5 160 100 100 14 0.0 160 86 100 1.16 2.5 0.974
SO
1% 4 1 5 80 20 100 11 2.4 80 11 98 1.36 7.7 0.999
3% 4 3 5 80 60 100 0 0.1 80 60 100 2.00 8.1 0.992
10% 4 10 5 80 200 100 5 0.5 80 196 100 3.70 16.2 0.982
15% 4 15 5 80 300 100 27 1.7 80 275 98 4.66 24.9 0.996
DPH
3% 4 5 3 80 100 60 13 0.9 80 88 59 1.83 8.0 0.999
8% 4 5 8 80 100 160 19 1.6 80 83 158 3.02 17.5 0.999
a Calculated from applied amount and released amount.
b Calculated from residual amount of each ingredient; (DPHþSO)/PMB.
c Apparent release rate calculated from slope of Higuchi’s plots of release study.
d Square of correlation coefﬁcient of Higuchi’s plot regression.
e Oil phase weight absorbed to paper.
f Y-intercept of Higuchi’s plot of DPH release.
Fig. 7. The relation between the ratio of oil phase/PMB in the formulation and
apparent release rate.
Fig. 8. Speculation of EL condition after application of the practical dose to
the skin.
A. Ishikawa et al. / Results in Pharma Sciences 2 (2012) 16–22 21(MPMB) showed good correlation (Fig. 7):
k¼ 4:8Moil=MPMB ð2Þ
For a homogeneous matrix, apparent release rate is expressed as
k¼ 2C0ðD=pÞ0:5 ð3Þ
where C0 is DPH concentration in dried ELs and D is the diffusion
constant in the matrix. In this case, C0 is expressed as
C0 ¼MDPH=Mtotal ð4Þ
where MDPH and Mtotal is residual amount of DPH and EL
(SOþDPHþPMB) at time 0 h, respectively. From Eqs. (2), (3), and




This shows that D0.5 is correlated with the reciprocal of PMB
concentration in residual EL and DPH concentrations in the oil phase.
A proposed mechanism is shown in Fig. 8. In the EL, the oil phase
is covered with PMB, which acts like a nanocapsule. When the
emulsion is applied on skin and dried, the emulsion is not converted
into a w/o emulsion, but becomes a thin ﬁlm of polymer containingthe oil phase. The ﬁlm is homogeneous from a macro view, so the
release of DPH occurs in a controlled matrix-type diffusion. The
dried EL consisted of two different phases. The DPH existed in the oil
phase, and diffusion through the PMB layer was rate limiting; thus,
the concentration of PMB in the matrix affected D.4. Conclusions
An emulsion lotion with controlled release function was
prepared. When a PMB EL was applied to skin with practical
dose, a thin ﬁlm formed after evaporation of water without phase
conversion of the emulsion. The release pattern of DPH was of a
matrix type and could be controlled by the ratio of the oil phase to
PMB. The penetration of DPH into skin could be controlled even if
the skin barrier function was compromised.
A PMB EL can function as a controlled release formulation for
application to the scalp or large areas of skin.Acknowledgments
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